Literature DB >> 32574

Dopaminergic supersensitivity after neuroleptics: time-course and specificity.

P Muller, P Seeman.   

Abstract

It is known that a single dose of a neuroleptic can elicit dopaminergic supersensitivity in animals. On the other hand, the clinical syndrome of tardive dyskinesia takes many months of years to develop. To resolve this apparent discrepancy, it is possible that subclinical or latent tardive dyskinesia is fully compensated in most patients taking neuroleptics. In others, where the tardive dyskinesia is full-blown and grossly apparent, the dopaminergic supersensitivity may be decompensated. Such compensatory and decompensatory phases have been proposed earlier by Hornykiewicz (1974), in the case of Parkinson's Disease. Dopaminergic supersensitivity persists for a period proportional to the lenght of the neuroleptic treatment. It is not yet clear whether the relation between the length of treatment and the persistence of supersensitivity holds for very long treatments, but in principle the relationship might account for the persistence of tardive dyskinesia after years of neuroleptic pretreatment.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 32574     DOI: 10.1007/bf00429171

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  71 in total

1.  Dopamine receptor binding in the corpus striatum of mammalian brain.

Authors:  D R Burt; S J Enna; I Creese; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1975-11       Impact factor: 11.205

2.  Amphetamine-induced dopaminergic hypersensitivity in guinea pigs. Implications in psychosis and human movement disorders.

Authors:  H L Klawans; D I Margolin
Journal:  Arch Gen Psychiatry       Date:  1975-06

3.  Long-term changes in the sensitivity of pre-and postsynaptic dopamine receptors in mouse striatum evidenced by behavioural and biochemical studies.

Authors:  M P Martres; J Costentin; M Baudry; H Marcais; P Protais; J C Schwartz
Journal:  Brain Res       Date:  1977-11-11       Impact factor: 3.252

4.  Changes in sensitivity to apomorphine during morphine dependence and withdrawal in rats.

Authors:  B Cox; M Ary; P Lomax
Journal:  J Pharmacol Exp Ther       Date:  1976-03       Impact factor: 4.030

5.  Evidence that methadone blocks dopamine receptors in the brain.

Authors:  H A Sasame; J Perez-Cruet; G Di Chiara; A Tagliamonte; P Tagliamonte; G L Gessa
Journal:  J Neurochem       Date:  1972-08       Impact factor: 5.372

6.  Neuroleptic and non-neuroleptic catalepsy.

Authors:  B Costall; R J Naylor
Journal:  Arzneimittelforschung       Date:  1973-05

7.  Rapid development of hypersensitivity of striatal dopamine receptors induced by alpha-methylparatyrosine and its prevention by protein synthesis inhibitors.

Authors:  J Costentin; H Marçais; P Protais; M Baudry; S De La Baume; M P Martres; J C Schwartz
Journal:  Life Sci       Date:  1977-08-01       Impact factor: 5.037

8.  The effect of long-term ethanol treatment on the sensitivity of the dopamine receptors in the nucleus accumbens.

Authors:  J Engel; S Liljequist
Journal:  Psychopharmacology (Berl)       Date:  1976-09-29       Impact factor: 4.530

9.  Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs.

Authors:  C Erzin-Waters; P Muller; P Seeman
Journal:  Can J Physiol Pharmacol       Date:  1976-08       Impact factor: 2.273

10.  L-3,4-dihydroxyphenylalanine-induced hypersensitivity simulating features of denervation.

Authors:  L C Tang; G C Cotzias
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

View more
  41 in total

Review 1.  Antipsychotic dosing: how much but also how often?

Authors:  Gary Remington; Shitij Kapur
Journal:  Schizophr Bull       Date:  2010-07-21       Impact factor: 9.306

2.  Characterization of the 5' flanking region of the human D1A dopamine receptor gene.

Authors:  M T Minowa; T Minowa; F J Monsma; D R Sibley; M M Mouradian
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

Review 3.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

4.  Chronic low-dose haloperidol effects on self-stimulation rate-intensity functions.

Authors:  M R Lynch; R J Carey
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 5.  Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia.

Authors:  J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  Altered spontaneous behavior and sensitivity to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine.

Authors:  A Campbell; R J Baldessarini; J L Neumeyer
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Induction of dopaminergic supersensitivity after a single dose of the neuroleptic isofloxythepin.

Authors:  M Valchár; J Metysová; J Chlebounová; A Dlabac
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

8.  Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics.

Authors:  L Tune; J T Coyle
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  Changes of response to dopaminergic drugs in rats submitted to REM-sleep deprivation.

Authors:  S Tufik
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

10.  Differences between antipsychotic drugs in persistence of brain levels and behavioral effects.

Authors:  B M Cohen; T Tsuneizumi; R J Baldessarini; A Campbell; S M Babb
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.